News
06-06-2010, 10:47 PM
Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).
More... (http://www.news-medical.net/news/20100607/Celldex-Therapeutics-reports-mature-data-from-CDX-011-Phase-12-study-in-advanced-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20100607/Celldex-Therapeutics-reports-mature-data-from-CDX-011-Phase-12-study-in-advanced-breast-cancer.aspx)